Back to discover
Drug

Vorinostat

In clinical development
ClassHistone deacetylase 1 inhibitorEmerging researchLate-stage developmentCooling momentum
Also known as Octanedioic acid hydroxyamide phenylamide, SAHA, SHH, Suberanilohydroxamic acid+3 more

Octanedioic acid hydroxyamide phenylamide, SAHA, SHH, Suberanilohydroxamic acid, Suberoylanilide hydroxamic acid, Zolinza, Vorinostatum.

RxNorm194337ChEMBLCHEMBL98ATCL01XH01UNII58IFB293JI
14
Research papers
27
Active clinical trials
4
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies

Clinical trial2026-07-30Primary completion · ClinicalTrials.gov

An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn's Disease, Ulcerative Colitis, and Chronic Granulomatous Disease Colitis Patients and Maintenance Therapy With Ustekinumab

Clinical trial2026-07-08Results expected Q2 2035 · ClinicalTrials.gov

A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical trial2026-07-02Results posted · ClinicalTrials.gov

A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Clinical trial2026-07-02Results posted · ClinicalTrials.gov

Use of Vorinostat as GVHD Prophylaxis in Children, Adolescents, and Young Adults With Non-Malignant Disorders Undergoing Allogeneic Blood and Marrow Transplantation

Clinical trial2026-06-30Results expected Q2 2028 · ClinicalTrials.gov

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Clinical trial2026-06-24Results posted · ClinicalTrials.gov

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Clinical trial2026-06-17Results expected Q3 2026 · ClinicalTrials.gov

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Clinical trial2026-06-03Results expected Q4 2028 · ClinicalTrials.gov

Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy.

Research2024-05-01Cancer research

Suberoylanilide Hydroxamic Acid (SAHA) Is a Driver Molecule of Neuroplasticity: Implication for Neurological Diseases.

Research2023-08-24Biomolecules

Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.

Research2015-06-20Investigational new drugs

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.

Research2015-03-20The Lancet. Oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vorinostat
Aliases & brands
Octanedioic acid hydroxyamide phenylamideSAHASHHSuberanilohydroxamic acidSuberoylanilide hydroxamic acidZolinzaVorinostatum
RxNorm CUI
194337
ChEMBL ID
CHEMBL98
ATC codes
L01XH01
UNII
58IFB293JI
Primary mechanism
Histone deacetylase 1 inhibitor

Pharmacology & targets

4 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Histone deacetylase 1
HDAC1 · Q13547
INHIBITORHistone deacetylase 1 inhibitor
Histone deacetylase 3
HDAC3 · O15379
INHIBITORHistone deacetylase 3 inhibitor
Protein deacetylase HDAC6
HDAC6 · Q9UBN7
INHIBITORHistone deacetylase 6 inhibitor
Histone deacetylase 2
HDAC2 · Q92769
INHIBITORHistone deacetylase 2 inhibitor

Clinical trials

195 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
195
registered trials across all phases
LATEST COMPLETION 2025
27
Active studies
11
Recruiting
12
Late-stage (III+)
118
Completed
50
Discontinued
PHASE DISTRIBUTIONn = 195
Early Phase 11Phase 173Phase 1 / 241Phase 268Phase 2 / 33Phase 35Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruitingPH II/IIISt. Jude Children's Research Hospitaln=7902028

A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas

CompletedPH II/IIINational Cancer Institute (NCI)n=1012023

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

CompletedPH IIIKyowa Kirin, Inc.n=3722021

A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)

CompletedPH IIINational Cancer Institute (NCI)n=7542017

An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma

CompletedPH IIIMerck Sharp & Dohme LLCn=6372015

Recent completions

Trials that read out recently, adding to the completed evidence base.

Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas

CompletedPH IM.D. Anderson Cancer Centern=502025

A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) With Temsirolimus in Children With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (DIPG)

CompletedPH IM.D. Anderson Cancer Centern=182025

A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas

CompletedPH II/IIINational Cancer Institute (NCI)n=1012023

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

CompletedPH I/IIThe Netherlands Cancer Instituten=332023

A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies

CompletedPH I/IIUniversity of Washingtonn=502023

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

CompletedPH IINational Institute of Allergy and Infectious Diseases (NIAID)n=312023

Research activity

14 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20092024
Most influential

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Nature · 2012 · 984 cites

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

The Journal of infectious diseases · 2014 · 203 cites

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.

The Lancet. Oncology · 2015 · 151 cites

Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.

The Lancet. Oncology · 2014 · 102 cites

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

British journal of haematology · 2014 · 89 cites

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

Clinical lymphoma & myeloma · 2009 · 62 cites
Recent papers

Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy.

Cancer research · 2024 · 47 cites

Suberoylanilide Hydroxamic Acid (SAHA) Is a Driver Molecule of Neuroplasticity: Implication for Neurological Diseases.

Biomolecules · 2023 · 9 cites

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.

The Lancet. Oncology · 2015 · 151 cites

Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.

Investigational new drugs · 2015 · 43 cites

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.

Leukemia & lymphoma · 2015 · 6 cites

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

The Journal of infectious diseases · 2014 · 203 cites
Major research themes8
Diet, Ketogenic1Drug Resistance, Neoplasm1Epigenesis, Genetic1Hematopoietic Stem Cell Transplantation1Histone Deacetylase Inhibitors1Immune Checkpoint Inhibitors1Nervous System Diseases1Neuronal Plasticity1
Journals, researchers & institutions
Top journals
  • Investigational new drugs2
  • The Lancet. Oncology2
  • Biomolecules1
  • British journal of haematology1
  • Cancer research1
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
Leading researchers
  • Anderson EM2
  • Archin NM2
  • Bosch RJ2
  • Coffin JM2
  • Crooks AM2
  • Eron JJ2
  • Hazuda DJ2
  • Kashuba AD2
Leading institutions
free-text, unnormalised
  • National Cancer Institute2
  • A.O.R.N. S. Anna and S. Sebastiano Hospital1
  • Boler-Parseghian Center for Rare and Neglected Diseases1
  • Centre Hospitalier Regional Universitaire de Lille1
  • Columbia University1
  • Cross Cancer Institute/University of Alberta1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

3-Hydroxybutyric Acid

Studied across the same disease area as Vorinostat in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials